Prostat First Aid Burn Ease, 0.9g Gel
NDC Package 58228-2012-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Prostat First Aid Burn Ease, 0.9g (lidocaine) gel is a medication used to help reduce itching and pain from certain skin conditions (such as scrapes, minor skin irritations, insect bites). This formulation utilizes a gel delivery system. Marketed by Prostat First Aid Llc, this product is identified by NDC 58228-2012 and is authorized under FDA application M017.

Identification & Billing

NDC Package Code
58228-2012-1
Package Description
900 BOX in 1 CARTON / 25 PACKET in 1 BOX / .9 g in 1 PACKET
Product Code
11-Digit Billing Format
58228201201
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Prostat First Aid Burn Ease, 0.9g
Non-Proprietary Name
Lidocaine
Substance Name
Lidocaine Hydrochloride
Dosage Form
Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Usage Information
This product is used to help reduce itching and pain from certain skin conditions (such as scrapes, minor skin irritations, insect bites). It may also be used to help relieve nerve pain after shingles (infection with herpes zoster virus). Lidocaine belongs to a class of drugs known as local anesthetics. It works by causing a temporary loss of feeling in the area where you apply the patch.

Regulatory & Marketing

Labeler Name
Prostat First Aid Llc
Product Type
Human Otc Drug
FDA Application #
M017
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
09-30-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58228-2012-1 identifies a specific commercial package of 900 box in 1 carton / 25 packet in 1 box / .9 g in 1 packet of Prostat First Aid Burn Ease, 0.9g, a human over the counter drug labeled by Prostat First Aid Llc. This gel is formulated for topical use and contains lidocaine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Prostat First Aid Llc on September 30, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This product is used to help reduce itching and pain from certain skin conditions (such as scrapes, minor skin irritations, insect bites). It may also be used to help relieve nerve pain after shingles (infection with herpes zoster virus). Lidocaine belongs to a class of drugs known as local anesthetics. It works by causing a temporary loss of feeling in the area where you apply the patch.

How is this Prostat First Aid Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58228201201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
58228-2012-1
11-Digit CMS (5-4-2)
58228-2012-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.